José Luis L.
- Country
- Spain
- Department
- Dermatology
Research Overview
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- A Phase 2b Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ritlecitinib in Adult Participants with Chronic Spontaneous Urticaria
- Efficacy and Safety of Oral Decitabine and Ivosidenib in Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
Data & Insights
Has run more than one trial at 225 of 480 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the treatment of acute myeloid leukemia (AML), with particular expertise in genetic mutation-specific approaches to therapy.
- IDH1-mutated AML management
- FLT3-ITD negative AML treatment
- Novel therapeutic combinations
Their research encompasses innovative treatment strategies for patients who cannot receive intensive chemotherapy.
Precision Medicine
The investigator focuses on mutation-targeted therapeutic approaches in blood cancers, particularly exploring treatments based on specific genetic markers.
- Targeted therapy development
- Genetic mutation analysis
- Personalized treatment strategies
Their work includes evaluation of targeted agents in combination with standard treatments.
Clinical Development
The investigator's expertise extends to the development of novel therapeutic agents for hematologic malignancies.
- Combination therapy assessment
- Treatment tolerability studies
- Long-term therapeutic outcomes
Their research includes evaluation of maintenance therapy approaches in AML treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.